Off Label NCCN denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for off label nccn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This Off-Label (NCCN-Supported) Drug as Duplicate Therapy

Humana's duplicate-therapy denial means the plan's automated review flagged that you are already receiving — or have recently received — a drug it considers therapeutically equivalent to the one your prescriber requested. For NCCN-supported off-label oncology or hematology agents, this flag is frequently inaccurate: two drugs within the same broad class can have meaningfully different mechanisms, resistance profiles, or tolerability characteristics that make concurrent or sequential use clinically rational.

## Why This Is Appealable

NCCN Compendium listings are widely recognized by state insurance codes and by CMS as a standard of care reference for off-label oncology drug use. If Humana's policy acknowledges NCCN compendium support as a coverage basis, a duplicate-therapy denial that ignores the specific NCCN category recommendation for your regimen is inconsistent with that policy. Your prescriber is in the best position to explain why the requested agent is not interchangeable with what you are already taking.

## Federal Appeal Framework

• Internal appeal: File within the timeframe printed on your Explanation of Benefits (EOB) — typically 180 days from the denial date. Request Humana's complete clinical review criteria in writing.
• External review (ACA §2719): If Humana upholds the denial internally, you have the right to an independent external review by an accredited Independent Review Organization (IRO). The standard window is roughly four months from the final internal denial; an expedited track (72-hour decision) is available when your health would be seriously jeopardized by delay.
• ERISA §503 (employer plans): Self-funded employer plans must provide a full-and-fair review. You may request the specific clinical guidelines Humana applied.

## Documentation to Gather

1. Diagnosis confirmation — pathology report, staging workup, and current treatment summary establishing the exact disease type and line of therapy. 2. Current and prior treatment history — a dated list of every agent you have received, with start/stop dates and documented outcomes or toxicities. 3. Why the drugs differ — a prescriber letter explaining the distinct mechanism, resistance profile, or safety rationale that makes the requested drug non-duplicative. 4. NCCN compendium citation — print the applicable NCCN category listing for this drug/indication combination directly from NCCN.org; attach it to the appeal. 5. Humana's own policy — obtain Humana's published coverage policy and duplicate-therapy definition; quote their own language back to them.

## Criteria-Mapping Structure

Create a table with two columns: Humana's stated duplicate-therapy criteria (from the denial letter and the published policy) and How your chart addresses each criterion. For every requirement Humana lists — such as "same mechanism of action" or "same therapeutic class" — provide the prescriber's documented explanation of why that criterion is not met in your specific case. Attach supporting clinical records for each row.